November 13, 2026 · Chest · DOI: 10.1016/j.chest.2026.11.005

Comparative Effectiveness of GLP-1 Receptor Agonists versus DPP-4 and SGLT2 Inhibitors in Patients with Bronchiectasis and Type 2 Diabetes.

Listen to this summary

In this TriNetX retrospective cohort study of patients with bronchiectasis and type 2 diabetes, the authors asked whether GLP-1 receptor agonist use is associated with better outcomes than DPP-4 inhibitor or SGLT2 inhibitor use. After propensity score matching, GLP-1RA users had significantly lower all-cause mortality and reduced risks of acute respiratory failure and lower respiratory tract infection compared with either comparator, though no significant reduction in bronchiectasis exacerbations was seen. Because this is an observational design, the findings suggest a possible disease-modifying role for GLP-1RAs in bronchiectasis but do not establish causation.

Kuo-Ming Liao, Yao-Ming Chuang, Wan-Hsuan Hsu, Chia-Yu Kuo, Jheng-Yan Wu, Bo-Wen Shiau, Konstantinos Kostikas, Gerard J Criner, Chih-Cheng Lai

This is one of 33,000+ journals available on OSLR. Try it free for 14 days.

Free 14-day trial. 33,000+ journals. Cancel anytime.

14-day free trial. No commitment.

“

"Oslr has become part of my weekly routine on my day off. The clinical relevance of the summaries is outstanding — I'd rate it 9/10. Being able to consume research hands-free is a huge advantage for busy physicians."

Dr. Jennifer Thompson

Dr. Jennifer Thompson

Portland, OR

Stay current without falling behind

33,000+ journals. 3-minute audio summaries. Free for 14 days.

Download on the App StoreGet it on Google Play